| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2005.03.3266 |
| P698 | PubMed publication ID | 16361630 |
| P50 | author | Edith A. Perez | Q18389345 |
| David Flockhart | Q23563106 | ||
| Fergus J. Couch | Q63018779 | ||
| Zeruesenay Desta | Q87723626 | ||
| Sean C Harrington | Q89442891 | ||
| James N Ingle | Q89668737 | ||
| James M Rae | Q89749499 | ||
| Stephanie L Safgren | Q92977647 | ||
| Matthew P Goetz | Q95259846 | ||
| Vera J Suman | Q96186734 | ||
| Daniel W Visscher | Q108126317 | ||
| Wilma L Lingle | Q112850014 | ||
| Matthew M Ames | Q116795042 | ||
| P2093 | author name string | Carol Reynolds | |
| P433 | issue | 36 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tamoxifen | Q412178 |
| P304 | page(s) | 9312-9318 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes | |
| P478 | volume | 23 |
| Q53116333 | A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors. |
| Q52649004 | A computational approach predicting CYP450 metabolism and estrogenic activity of an endocrine disrupting compound (PCB-30). |
| Q36026558 | A decade of letrozole: FACE |
| Q28943542 | A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese |
| Q42590601 | A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? |
| Q33451759 | A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7. |
| Q46642125 | A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab |
| Q33914381 | A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast |
| Q36808170 | ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen |
| Q37515404 | Adjuvant endocrine therapy for premenopausal women with breast cancer |
| Q80482657 | Adjuvant endocrine therapy for premenopausal women with early breast cancer |
| Q39872708 | Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview |
| Q34774649 | Adjuvant hormonal therapy in premenopausal women with operable breast cancer: not-so-peripheral perspectives |
| Q37608406 | Advances in the adjuvant and neoadjuvant treatment of breast cancer |
| Q33631047 | American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer |
| Q37219099 | Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells |
| Q33565033 | An inter-professional approach to personalized medicine education: one institution's experience |
| Q40364215 | Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. |
| Q37205521 | Are we HER-ting for innovation in neoadjuvant breast cancer trial design? |
| Q81235295 | Aromatase inhibitors and tamoxifen: where do we go from here? |
| Q46648287 | Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. |
| Q37352049 | Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort |
| Q35006860 | Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen |
| Q35158757 | Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment |
| Q37140638 | Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and clinical outcomes of Thai breast cancer patients treated with tamoxifen |
| Q38946003 | Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Women's Health Initiative Study |
| Q37121685 | Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. |
| Q33611502 | Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| Q38357424 | Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer |
| Q34095977 | Breast Cancer Systemic Therapy: The Need for More Economically Sustainable Scientific Strategies in the World |
| Q24602679 | Breast Cancer in the Personal Genomics Era |
| Q37608335 | Breast cancer in young women: climbing for progress in care and knowledge |
| Q36459134 | Breast cancer recurrence risk in relation to antidepressant use after diagnosis |
| Q34949553 | Breast cancer: a neglected disease for the majority of affected women worldwide |
| Q37598890 | Breast cancer: beyond the cutting edge |
| Q30419845 | Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research |
| Q37353704 | CYP19 genetic polymorphism haplotype AASA is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer |
| Q38442184 | CYP2C19*2 Polymorphism is Associated with Increased Survival in Breast Cancer Patients Using Tamoxifen |
| Q40382805 | CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients |
| Q87856738 | CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart |
| Q36727678 | CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients |
| Q46519655 | CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients |
| Q34993830 | CYP2D6 and tamoxifen: DNA matters in breast cancer |
| Q21195205 | CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen |
| Q37524058 | CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations |
| Q35009604 | CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis |
| Q35842986 | CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial |
| Q34205830 | CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies |
| Q57561007 | CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial |
| Q48030851 | CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial |
| Q38668766 | CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study |
| Q38123038 | CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients |
| Q36109257 | CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects. |
| Q34065337 | CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer |
| Q30400967 | CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine |
| Q44624989 | CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies |
| Q36545056 | CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. |
| Q53355927 | CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients. |
| Q46802987 | CYP2D6 phenotype prediction from genotype: which system is the best? |
| Q37738765 | CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance |
| Q38109822 | CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis |
| Q36441557 | CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients |
| Q36836671 | CYP2D6 testing in breast cancer: ready for prime time? |
| Q57585515 | CYP450 genotype and pharmacogenetic association studies: a critical appraisal |
| Q79633839 | Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments? |
| Q36822291 | Cancer pharmacogenomics |
| Q34315833 | Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation |
| Q30668728 | Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis |
| Q79448439 | Chemoprevention of breast cancer with selective oestrogen-receptor modulators |
| Q39744296 | Circadian rhythm of hot flashes and activity levels among prostate cancer patients on androgen deprivation therapy |
| Q49554838 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy |
| Q34095909 | Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer |
| Q92617290 | Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites |
| Q35911174 | Clinical and biomarker predictors of side effects from tamoxifen |
| Q35058455 | Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes |
| Q36248267 | Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism |
| Q35032378 | Clinically relevant genetic variations in drug metabolizing enzymes |
| Q30416074 | Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond |
| Q43477148 | Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer. |
| Q37464084 | Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. |
| Q35987488 | Course and Moderators of Hot Flash Interference during Androgen Deprivation Therapy for Prostate Cancer: A Matched Comparison. |
| Q37306557 | Current research topics in endocrine therapy for breast cancer |
| Q39042324 | Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity |
| Q34346501 | Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients |
| Q37000701 | Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance |
| Q37016004 | Defining a global research agenda for breast cancer |
| Q34502648 | Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in São Luís, Brazil, and its association with prognostic factors and disease-free survival |
| Q53110628 | Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. |
| Q37179165 | Dietary change and reduced breast cancer events among women without hot flashes after treatment of early-stage breast cancer: subgroup analysis of the Women's Healthy Eating and Living Study |
| Q22000762 | Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer? |
| Q37271799 | Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes? |
| Q37284439 | Drug interactions and pharmacogenomics in the treatment of breast cancer and depression |
| Q38218657 | Drug resistance to targeted therapies: déjà vu all over again |
| Q37811052 | Drug–drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice |
| Q46712952 | Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy |
| Q57142283 | Early breast cancer |
| Q46981180 | Early discontinuation of tamoxifen: a lesson for oncologists |
| Q51016808 | Effect of CYP2D6 polymorphisms on breast cancer recurrence. |
| Q34278391 | Effects of CYP induction by rifampicin on tamoxifen exposure |
| Q35884159 | Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen |
| Q37997046 | Efficacy and pharmacogenomic biomarkers in breast cancer |
| Q43121565 | Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial |
| Q38221463 | Emerging strategies to overcome resistance to endocrine therapy for breast cancer |
| Q54966058 | Endocrine Treatment-Related Symptoms and Patient Outcomes in Breast Cancer: A Meta-Analysis. |
| Q82750609 | Endocrine symptoms to predict risk of recurrence? |
| Q57108564 | Endocrine therapy for breast cancer in the primary care setting |
| Q37385376 | Endocrine therapy for the treatment of postmenopausal women with breast cancer |
| Q34146176 | Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects |
| Q37103134 | Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy |
| Q37435948 | Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen |
| Q35558946 | Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen |
| Q92240915 | Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression |
| Q37876401 | Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs |
| Q35510803 | Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials |
| Q33926313 | Expectations, validity, and reality in pharmacogenetics |
| Q34793924 | Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis |
| Q37597968 | Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry |
| Q34449535 | Feeling too hot or cold after breast cancer: is it just a nuisance or a potentially important prognostic factor? |
| Q47884041 | First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer |
| Q37162200 | Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population |
| Q35647154 | Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction |
| Q36550926 | Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer |
| Q37195375 | Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites |
| Q79709460 | Gene expression profiling of breast cancer |
| Q37126673 | Genelex Corporation |
| Q58388072 | Genetic association studies: where are we now? |
| Q37698407 | Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity |
| Q46154968 | Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen |
| Q36410400 | Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer |
| Q35749331 | Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer |
| Q36950502 | Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation. |
| Q37085992 | Genotype-guided adjuvant endocrine therapy: new tricks from an old drug? |
| Q35172199 | Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study |
| Q36218210 | Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses |
| Q59504056 | Germline oncopharmacogenetics, a promising field in cancer therapy |
| Q42587324 | Germline pharmacogenetics of tamoxifen response: have we learned enough? |
| Q51948740 | Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. |
| Q34376302 | High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissues |
| Q92091777 | Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients |
| Q37992403 | Hormonal therapy in breast cancer: a model disease for the personalization of cancer care |
| Q35076890 | Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites |
| Q27026180 | Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen |
| Q92253098 | Impact of CYP2D6 Polymorphisms on Tamoxifen Treatment in Patients With Retroperitoneal Fibrosis: A First Step Towards Tailored Therapy? |
| Q38017920 | Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we? |
| Q46738253 | Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy |
| Q34976487 | Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients |
| Q49048955 | Impact of four loci on serum tamsulosin hydrochloride concentration |
| Q53831501 | Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. |
| Q38105253 | Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies |
| Q37355945 | In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast |
| Q80976481 | Inappropriate ATAC on tamoxifen |
| Q84911127 | Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score |
| Q43987491 | Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer. |
| Q64271746 | Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor |
| Q36847276 | Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs |
| Q91972922 | Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen |
| Q37511330 | Is tamoxifen a genotoxic carcinogen in women? |
| Q92579654 | LINC00309 is associated with short disease-free survival in breast cancer |
| Q38041388 | Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. |
| Q33630784 | Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. |
| Q84903909 | Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age |
| Q34095952 | Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics. |
| Q35732619 | Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer. |
| Q41738179 | Linker design for the modular assembly of multifunctional and targeted platinum(ii)-containing anticancer agents |
| Q89941347 | Lobular breast carcinoma metastatic to the endometrium in a patient under tamoxifen therapy: A case report |
| Q36047387 | Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. |
| Q37350187 | Management of complications from estrogen deprivation in breast cancer patients |
| Q27011221 | Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA |
| Q37750046 | Mechanisms of resistance to hormonal treatment in breast cancer |
| Q37217582 | Metabolic activity in the insular cortex and hypothalamus predicts hot flashes: an FDG-PET study |
| Q37722954 | Molecular epidemiology and its current clinical use in cancer management |
| Q37613529 | Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment |
| Q37608272 | Molecular mechanisms and mode of tamoxifen resistance in breast cancer |
| Q33560299 | Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions |
| Q33841512 | New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis |
| Q36927087 | New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer |
| Q37231522 | Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis |
| Q91238280 | Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer |
| Q45930220 | No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. |
| Q37301707 | North Central Cancer Treatment Group--achievements and perspectives |
| Q34386787 | Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial |
| Q37738877 | Optimal adjuvant endocrine therapy for early breast cancer |
| Q82780432 | Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen |
| Q37564485 | Overcoming drug resistance in patients with metastatic breast cancer |
| Q30440152 | Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene |
| Q37883726 | Part 1: background, methodology, and clinical adoption of pharmacogenetics |
| Q35584977 | Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism |
| Q33760585 | Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer |
| Q33602704 | Paving the Way to Personalized Genomic Medicine: Steps to Successful Implementation |
| Q38141971 | Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice |
| Q36336007 | Personalized medicine: is it a pharmacogenetic mirage? |
| Q30319697 | Perspectives on Breast Cancer Management: Tailoring Treatment to the Individual Patient |
| Q33855494 | PharmGKB summary: tamoxifen pathway, pharmacokinetics |
| Q53272686 | Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. |
| Q38214388 | Pharmacogenetic biomarkers for predicting drug response. |
| Q37768070 | Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. |
| Q34136250 | Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application |
| Q37201611 | Pharmacogenetic treatments for drug addiction: alcohol and opiates. |
| Q34982551 | Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine |
| Q35097430 | Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response? |
| Q37772183 | Pharmacogenetics and human genetic polymorphisms |
| Q36719659 | Pharmacogenetics and oncology treatment for breast cancer |
| Q35030489 | Pharmacogenetics and pharmacogenomics of anticancer agents. |
| Q37039787 | Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer |
| Q37725978 | Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab |
| Q36441485 | Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management |
| Q37657531 | Pharmacogenetics in reproductive and perinatal medicine |
| Q38003704 | Pharmacogenetics of aromatase inhibitors. |
| Q37633176 | Pharmacogenetics of breast cancer therapies |
| Q38003703 | Pharmacogenetics of chemotherapy efficacy in breast cancer |
| Q38388873 | Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. |
| Q37312970 | Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q31144283 | Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment |
| Q37378994 | Pharmacogenomic progress in individualized dosing of key drugs for cancer patients |
| Q35955515 | Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others |
| Q33828149 | Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis |
| Q48125765 | Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q27006783 | Pharmacogenomics of breast cancer therapy: an update |
| Q46856156 | Pharmacogenomics of tamoxifen and aromatase inhibitors |
| Q38364888 | Pharmacogenomics toward personalized tamoxifen therapy for breast cancer |
| Q91715206 | Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms |
| Q34137575 | Pharmacogenomics: a systems approach |
| Q37305039 | Pharmacogenomics: a tool for improving cancer chemotherapy |
| Q56898282 | Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study |
| Q37500096 | Pharmacology and pharmacogenetics of chemotherapeutic agents |
| Q43280939 | Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy |
| Q35975826 | Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance. |
| Q34632875 | Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. |
| Q37611786 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. |
| Q43244977 | Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. |
| Q94568684 | Posttraumatic stress disorder and breast cancer: Risk factors and the role of inflammation and endocrine function |
| Q37221922 | Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen |
| Q34774040 | Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors |
| Q64099527 | Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models |
| Q36691795 | Predicting risk of breast cancer recurrence using gene-expression profiling. |
| Q37678053 | Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer |
| Q27027277 | Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal |
| Q38963111 | Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis |
| Q57549090 | Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology |
| Q27852757 | RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial |
| Q82298915 | Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal breast cancer |
| Q43242124 | Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. |
| Q37382559 | Recent progress and clinical importance on pharmacogenetics in cancer therapy. |
| Q36090022 | Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. |
| Q57585715 | Research Highlights |
| Q45394201 | Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen |
| Q38305705 | Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy |
| Q38495339 | Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases. |
| Q36794420 | SERMs for the treatment and prevention of breast cancer |
| Q35605304 | SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen |
| Q36984515 | Selective estrogen receptor modulators and phytoestrogens |
| Q43042856 | Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality |
| Q33634928 | Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study |
| Q47099651 | Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients |
| Q34949446 | Sex hormone concentrations and the risk of breast cancer recurrence in postmenopausal women without hot flashes |
| Q37845827 | Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? |
| Q36752667 | Should pharmacogenomic studies be required for new drug approval? |
| Q59242456 | ShouldCYP2D6be genotyped when treating with tamoxifen? |
| Q36915143 | Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients |
| Q34914140 | Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes |
| Q84543679 | Some applications of pharmacogenomics and epigenetics in drug development and use in pursuit of personalized medicine |
| Q37039810 | Strength and weakness of phase I to IV trials, with an emphasis on translational aspects |
| Q44961520 | Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer |
| Q37345699 | Symptom management in premenopausal patients with breast cancer |
| Q33781027 | Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation |
| Q37091133 | Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity |
| Q37353826 | Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors |
| Q34244463 | Tamoxifen and CYP2D6: a contradiction of data |
| Q34805784 | Tamoxifen and ovarian function |
| Q28300092 | Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy |
| Q38859693 | Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors |
| Q46344167 | Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer |
| Q36946542 | Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response |
| Q37224555 | Tamoxifen resistance in breast cancer |
| Q37065730 | Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters |
| Q36953961 | Tamoxifen, hot flashes and recurrence in breast cancer. |
| Q44899685 | Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22. |
| Q24652988 | Tamoxifen: catalyst for the change to targeted therapy |
| Q92511817 | Targeted ultra-deep sequencing of a South African Bantu-speaking cohort to comprehensively map and characterize common and novel variants in 65 pharmacologically-related genes |
| Q37785219 | The Application of Genetics and Genomics to Cancer Prevention |
| Q35909573 | The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer |
| Q33664433 | The Impact of CYP2D6 Genotyping on Tamoxifen Treatment |
| Q54212765 | The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition. |
| Q54324247 | The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer. |
| Q26830744 | The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice |
| Q48584159 | The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen |
| Q28539057 | The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton |
| Q34253646 | The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer |
| Q36752662 | The pharmacogenetics research network: from SNP discovery to clinical drug response. |
| Q37772507 | The potential of knockout mouse lines in defining the role of flavin-containing monooxygenases in drug metabolism |
| Q36125546 | The potential of translational bioinformatics approaches for pharmacology research |
| Q36497088 | The role of genetic variability in drug metabolism pathways in breast cancer prognosis |
| Q34205869 | The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents |
| Q45905355 | The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels. |
| Q43185081 | Therapy: nonhormonal treatment of hot flashes-a viable alternative? |
| Q57580804 | To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancer |
| Q47295319 | Translational Biomedical Informatics and Pharmacometrics Approaches in the Drug Interactions Research |
| Q47427297 | Translational High-Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models |
| Q46270248 | Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial |
| Q36487328 | Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010. |
| Q33881477 | Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine. |
| Q35176493 | Tumorigenic effects of tamoxifen on the female genital tract. |
| Q37467243 | Update on the use of aromatase inhibitors in early-stage breast cancer |
| Q36729040 | Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study |
| Q37088243 | Vascular actions of estrogens: functional implications |
| Q37369803 | Vasomotor symptoms, adoption of a low-fat dietary pattern, and risk of invasive breast cancer: a secondary analysis of the Women's Health Initiative randomized controlled dietary modification trial |
| Q35691554 | What do we know about the mechanisms of aromatase inhibitor resistance? |
Search more.